Search

Introduction Restorative therapies are advertised as a cure for erectile dysfunction (ED) despite lack of data. One such therapy is platelet-rich plasma (PRP). PRP is created through centrifugation of autologous blood and separation of the platelet rich layer containing cytokines and growth factors involved in wound healing. We are conducting an ongoing, single center, prospective, one-to-one randomized, double blind, placebo controlled clinical trial assessing the safety and efficacy of PRP for ED (NCT04396795. Registered April 3, 2020). To reduce the variability in PRP concentration inherent to most PRP systems, we are using the Arthrex angel, the only system with an optical sensor to tailor PRP dose. Objective To assess the safety of injecting intracavernosal PRP in men with ED. Methods We retrospectively reviewed our clinical safety and adverse events data from September 2020 to May 2022. Patients receive either two injections of PRP or saline (placebo) four weeks apart. Patients were observed immediately post injection for adverse events. Additionally, patients were evaluated at 1-, 3- and 6-month periods. Finally, a Doppler ultrasound was completed at 6 months after last injection to assess for any structural or vascular changes to penis. For this analysis, we did not unblind patient groups. We report data from men who have received any injection with PRP or placebo and compared group A and B. We assessed statistical significance through t-test, where alpha=0.05. Results In total, 60 trial patients were included, 28 in group A and 32 in group B. There was no difference in pain with injection 1 (p=0.69) or injection two (p=0.99) (table 1). In each group, no major adverse events were recorded. In group A, only 1 minor adverse event, new penile plaque, was found (4.3%). This is similar to group B, where only 1 minor adverse event was reported (4.3%). No other minor adverse events were reported. Conclusions PRP appears safe to inject intracorporeally in patients with ED in our ongoing randomized placebo-controlled trial. Efficacy could not be assessed at this time. However, our study can help counsel patients on the side effects and complications associated with PRP. Disclosure No

2H-Azirine-2-carbonyl azides undergo a rearrangement into derivatives of 2-(1H-tetrazol-1-yl)acetic acid when interacting with O- and S-nucleophiles at room temperature. The reaction is catalyzed by tertiary amines or hydrazoic acid. The reaction with primary alcohols and phenols gives alkyl/aryl 2-(1H-tetrazol-1-yl)acetates. Thiophenols react with 2H-azirine-2-carbonyl azides to afford S-aryl 2-(1H-tetrazol-1-yl)ethanethioates. The mechanism of the nucleophile-induced rearrangement of 2H-azirine-2-carbonyl azides is discussed on the basis of DFT calculations as well as kinetic and 15N labeling experiments.

The article is devoted to the analysis of the impact of information technology on changes in the daily life of young people. The problem of escapism among young people is investigated by studying the records of the Hikikomori community in the VKontakte social network and the personal stories of subscribers in the Hikikomori telegram channel. In this work, escapism in online spaces is defined as an extreme manifestation of the virtualization of human everyday life.

Introduction Peyronie's Disease (PD) is prevalent in approximately 7.1% of the general population. Current treatment approaches include medical therapy and surgical intervention, and intervention only occurs once the disease process has entered the chronic, stable phase. The only FDA-approved medical therapy involves use of intralesional collagenase clostridium histolyticum injection and surgical interventions include tunica albuginea plication, plaque excision without grafting, or placement of penile prothesis. Additional PD therapies are needed as current treatment modalities have limited efficacy and considerable side effects. Platelet-derived therapies have seen increased use across various specialties in medicine, especially in orthopedics, due to their potential ability in wound healing and tissue regeneration. As calcified scar plaques are frequently identified in PD patients, autologous platelet rich plasma (PRP) may prove to be a viable treatment for this patient population. Objective We reviewed an initial series of patients receiving PRP vs placebo for PD to assess safety and feasibility among men recruited in a double-blind placebo controlled single-center clinical trial. Methods We reviewed data for men recruited into the clinical trial treated with PRP vs placebo at our center from April 2021 to July 2021. Patients were observed immediately post-injection and at follow-up for complications and tolerability. Where applicable, International Index of Erectile Function (IIEF-5) scores were reviewed before and after injections for PD. Results We report data from the men who have completed 2 completed injections (PRP or placebo). No post-procedural minor adverse events were seen in any of the men. None of them reported adverse effects such as penile bruising, swelling, edema, allergy, penile fracture, or mild pain at injection site. No patients experienced complications at follow-up. No worsening curvature was observed in men completing pre/post evaluations. Conclusions PRP appears to be a safe and feasible treatment modality in patients with PD from our limited data accumulated thus far in our ongoing randomized placebo-controlled trial with PRP for PD. Our study is the first study in the USA accruing men with PRP for PD and believe that safety and efficacy data accumulated from our study will be important for patient counseling. Disclosure No

Introduction Little is known of SARS-CoV2 (COVID-19) pathogenicity, but organ inflammation syndromes have been well observed and documented in the lungs, heart, liver, kidneys, and testes. While the blood-testis barrier is known to protect testes from antigens, current evidence suggests COVID-19 can affect the testis. Reports of bilateral orchitis are growing. Current hypotheses consider causes of (1) cellular induced cytokine storm or (2) IgG deposits in the vascular endothelium to be at blame but causal genes or underlying genetic susceptibility have not yet been identified. Objective This project sought to uncover genetic explanations as to why certain men face increased susceptibility to developing COVID orchitis. Methods We identified and examined six COVID-19 patients who all were confirmed with polymerase chain reaction (PCR), including three COVID-19 (+) men without orchitis (controls) and three COVID (+) men with orchitis (bilateral testicular pain for at least 5 days around the time of testing PCR positive). Of note, among the three men with COVID-19 who had orchitis, two of them were siblings. DNA extraction and whole exome sequencing were performed on blood using the QIAmp blood maxi kit on five of the six patients. Variants were prioritized by being shared between the three patients affected with orchitis, absent in controls, and introducing nonsense, frameshift, splicing or non-synonymous amino acid changes and less than 10% in population prevalence. Based on WES findings, DuoSet® Human ACE2 reagent kit 2 (catalog number: DY933-05) was purchased from R&D Systems, USA, and used to measure the level of soluble ACE2 in the plasma samples. Results The average age of the men in the study was 25 years old. The average duration of COVID symptoms (fever, sore throat, cough, body aches) were 7 days. Among the men who developed bilateral testis pain, the symptoms lasted for an average of 22 days. A list of 16 variants was generated that found to be shared between the two siblings with COVID orchitis along with the unrelated subject with COVID orchitis, and not present in the two controls. Among the 16 variants, a nonsynonymous non-frameshit deletion in NACAD variant on chromosome 7 with a frequency of 3.9% prevalence in ExAC was prioritized based on known involvement in the ACE2 pathway, read depth, and genotype quality. Phenotypically, we found that circulating levels of soluble ACE2 was 3.72 ng/ml among men who had COVID orchitis and was lower than men who developed COVID without orchitis. Conclusions We observed a stop mutation in NACAD in 2 brothers and 1 unrelated man who developed COVID orchitis. Interestingly, we found lower circulating ACE2 serum levels in both brothers with orchitis and the one nonrelated orchitis subject but normal serum levels in all controls. NACAD when involved with cellular ability to shuttle out ACE2 becomes critical for COVID symptomatology. With decreased transcellular and extracellular transport of ACE2 being possible in subjects with the gene mutation, it can be postulated more ACE2 will be found intracellularly leading to increased cellular entry of SARS CoV-2 and possibility of orchitis sequelae. Disclosure No

2

The article provides a brief historical overview of the requirements for the accounting of prospects of the development of infrastructure of railway stations and junctions that are contained in the regulations, as well as research and development, design, and other works. The information about the current approach to the accounting of the perspective of the development of design solutions is provided. Examples of schemes of the phased development of railway stations and junctions are presented.

Special linking circuits are required for the design of safe railway automation and remote control of trackside objects. They are usually based on devices with an asymmetrical failure rate, mainly first reliability class electromagnetic relays. The development of railway automation and remote control devices requires the use of state-of-the-art contactless semiconductor components. In this case, the use of functional converters or periodic testing of semiconductor switches and disconnection of the power supply from control objects in case of faults are needed. This article describes the use of a three-phase induction motor as the solution of the problem. They are used for the design of functional converters for railway automation electric motors control. It is proposed to use the low-frequency mode of power switch operation (switch frequency is 50 Hz) and to abandon the pulse-width modulation. The suggested technical solution is used in a CBI-MPC system for train traffic control at stations developed at the Center for Computer Railway Technologies of St. Petersburg State Transport University.

1. The positive results of grouting cracks in concrete of the upstream face of the Sayano-Shushenskoe dam are not limited to suppression of seepage between elevations 344 and 359 m. Substantial compression of concrete of the first column and beyond the limits of this zone at higher and lower elevations was obtained without advance of the cracks into the depths of the dam during injection of the grout under high pressures, which also prevented seepage. 2. It is necessary to consider well-founded the requirement of limiting additional opening of cracks during grouting to 1.5 mm. 3. When making calculations for estimating the effect of grouting on the SSS of the dam, one should not proceed from the average pressure in the crack being grouted, since its value is difficult to establish. It can tentatively be considered a rigid inserts over the entire front of the crack with a thickness on the upstream face of 1.75–2 mm and converging to 0 in the zone of joint I–II.

1. Designs which would preclude the possibility of occurrence of strong seepage through the concrete masonry should be provided for in structural members of high-head concrete dams to avoid the rapidly and markedly occurring process of piping of concrete and loss of its strength. 2. It was possible to suppress the concentrated high-head seepage in concrete on a considerable stretch along the front of the Sayano-Shushenskoe hydrostation dam only by means of nontraditional technologies and materials. 3. A study of the effect of the repair works on the stress—strain state of the dam lies ahead for research and design organization jointly with the Sayano-Shushenskoe hydrostation.

This article describes the construction and operation of a facility to dissipate the energy of the discharge from a high-head hydroelectric power plant. The Sayano-Shushenskoe hydro facility uses a hydraulic pump on a concrete platform with a baffle wall in a stilling basis. In this discussion, considerable attention is given to the stability and reliability of the platform, which operates under severe operating conditions. The provisions of reliability of this platform require observance of the rules of operating outlets, of careful monitoring of the operation of the outlets, the use during operation of the outlets of pumping the seepage waters of the drainage in the zone of the basin, and finally, the placement of diffusion blocks which make it possible to reduce by more than half the extreme values of the characteristics of the action of the discharge on the platform.

1. Constant monitoring of the stress-strain state of the Sayano-Shushenskoe gravityarch dam made it possible to substantiate the stages of filling the reservoir during temporary operation of the hydro development without detriment for the reliability of the structure. 2. The results of long-term monitoring of the dam indicates a satisfactory state of the structure at all stages of filling the reservoir and correspondence of the values of the parameters being monitored on site to their design premises (with the exception of stresses near the downstream face). 3. To obtain representative information it is necessary to provide in the design for routine correcting of the layouts of the MMI, particularly embedded instruments, depending on the technology of constructing the structure.

A remarkable event occurred in October 1975 at the construction of the world's largest hydroelectr ic station, the Sayano-Shushenskoeflooding of the first-stage construction, damming of the Enisei River channel, and moving of the river flow over the crest of the r ight-bank part of the dam (Fig. 1). This successfully completes the first stage of construction of the unique 242-m-high g rav i ty -a rch dam.

The authors put forward a program of prevention of dysplastic arthrosis which is presented in graphic form with textual description. It has been worked out on the basis of the formerly elaborated conceptual model "Dysplasia of the joint-dysplastic arthrosis" and it is a complex of general medical prophylactic measures oriented towards the elimination of mutagenous environmental factors, i.e. towards prevention of morbidity and towards the treatment-and-rehabilitation orthopaedic measures directed at reduction of the risk of development of dysplastic arthrosis in the conditions of dysplastic lesion of the joint (prevention of the disease). The conditions necessary for carrying out this program are supposed to be: a diagnostic algorithm providing for revealing dysplastic lesions already at the preclinical stage; thorough quantitative and qualitative characteristics of the dysplastic process providing for planning of correct surgical interventions; prognostic evaluations presuming a probability of evolution of the dysplastic process and its outcome; and a system of stage-by-stage diagnostic and treatment-and-rehabilitation measures providing for achievement of the effect expected in each particular case. Three groups of surgical interventions have been pointed out: prophylactic, which are performed on the dysplastic joint in case of absence of dystrophic changes; therapeutic, which are performed in case of presence of reversible dystrophic changes (e.g. chondromalation at stages I and II); and palliative, which only result in temporary stabilization of the arthrosis process, i.e. leading to improvement.

Aromatische Kohlenwasserstoffe wie (I) bilden mit dem Schwefel-Borfluorid- Komplex (II) in wasserfreiem HF die Triarylsulfoniumtetrafluoroborate (III).

: This article has been removed: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted at the request of the authors. The abstract was presented as a poster in the IMED last year. Our study was about the association of Ivermectin with reduction in mortality in COVID, a retrospective study with many limitations (which is innate in these types of studies). As in any retrospective study, we could not control for all the confounding variables, mainly severity of disease in patients treated with either ivermectin or remdesivir. Another important caveat is that it was conducted in July 2021, eight months ago, when we did not have all the clinical evidence we have right now about ivermectin in COVID-19. We were very clear in the abstract conclusions that our results are only showing an "association", they are not definitive, and further randomized clinical trials must be done to prove the efficacy of Ivermectin. However, the study has been misinterpreted by a significant number of people in the scientific community and the general population, stating that based on our study, ivermectin is effective to reduce COVID-19 mortality. We are really concerned about this problem because the patients may start taking or demanding this medication from their physicians, which can potentially be harmful. We know that a retrospective study like ours cannot be used to change or guide clinical practice. Retrospective studies are only helpful to formulate hypothesis that can be utilized to design clinical trials. This misrepresentation of the study may lead to a huge public health problem, since Ivermectin is a medication that is not FDA approved for COVID treatment, and currently has proven to be ineffective in clinical trials, which are truly the gold standard to evaluate the efficacy of a medication., (Copyright © 2021. Published by Elsevier Ltd.)